Cancer Biology
ISSN:
2150-1041 (print); ISSN: 2150-105X (online),
doi prefix: 10.7537,
Quarterly
Volume 5 / Issue 4, Cumulated No. 20, December 25, 2015
Cover, Introduction, Contents
You can use the message in end of the article abstract to
cite it.
To get Microsoft Documents: After you open the "Full Text" for each
article, change the last 3 characters of the web address from .pdf
to .doc (or .docx)
When you submit manuscript(s),
please mention that it is submitted to the Cancer Biology.
Marsland
Press,
PO Box 180432, Richmond Hill, New York 11418, USA, 347-321-7172
http://www.cancerbio.net
CONTENTS
No.
|
Titles /
Authors /Abstracts
|
Full Text
|
No.
|
1
|
Multiple myeloma in
Africa: review of an under-diagnosed carcinoma
Muhammad Sagir Shehu 1, Idris Abdullahi Nasir 2,
Anthony Uchenna Emeribe 3,
Jessy Thomas Medugu 2
1.
Immunology Unit, Department of Medicine, Ahmadu Bello
University, PMB 05 Zaria, Kaduna State, Nigeria
2.
Department of Medical Laboratory Science,
University of Maiduguri,
PMB 1069 Maiduguri,
Borno state, Nigeria.
3.
Department of Medical Laboratory Science, University of Calabar,
PMB 1115 Calabar, Cross River State, Nigeria
Email address:
eedris888@yahoo.com
Abstract:
Multiple myeloma (MM) is a blood carcinoma and gammopathy that
develops in the bone marrow. Normal antibody-producing plasma
cells transform into malignant myeloma cells. MM is the most
common hematologic cancer in African descends. Previous MM
findings suggest low survival rate in blacks. In MM, malignant
cells crowd out and inhibit the production of normal blood cells
and antibodies in the bone marrow. Since, this condition has
been established as a common blood cancer, it is crucial for
healthcare professionals
in African nations
to consider MM in differential diagnosis of blood-related
disorders. This mini-review summarized pertinent key concepts of
epidemiology, diagnosis and state of affairs of multiple myeloma
in Africa with the aim to suggest the need to use the
information herewith to incorporate MM international best
pathological practice.
[Muhammad
Sagir Shehu, Idris Abdullahi Nasir, Anthony Uchenna Emeribe,
Jessy Thomas
Medugu.
Multiple myeloma in
Africa: review of
an under-diagnosed carcinoma. Cancer Biology 2015;5(4):1-5].
(ISSN:
2150-1041).
http://www.cancerbio.net.
1. doi:10.7537/marscbj050415.01.
Keywords:
Multiple
myeloma; Immunopathology;
Blood
cancer; diagnosis; Africa |
Full Text |
1
|
2
|
Clinical outcomes of Basal versus Non-Basal clone in Triple
Negative Breast Cancer patients
Ashraf F. Barakat1, Fatma Z. Hussien1,
Dareen A. Mohamed2 and Radwa M.
Orbey2
Clinical Oncology1 and Pathology Department2,
Tanta University
FatmaZ_555@yahoo.com
Abstract:
Objective: The aim of this
study was to investigate the co-expression of basal markers in
triple negative breast cancer (TNBC) patients and to assess its
impact on survival, disease free and overall (DFS and OS).
Methods: This study was
conducted on 51 patients with TNBC subtype who were treated from
January 2009 until March 2013. All patients were evaluated by
immunohistochemical analysis for steroid hormones (ER, PR, HER.2
& Ki 67) and basal markers (CK5/6 & EGFR). They were
subsequently subdivided into two groups: basal group (n=24,
47.1%) and non-basal group (n=27, 52.9%). Basal markers
expression were correlated with clinicopathological factors
analyzed using the Chi square test and survival (DFS and OS)
using kaplan -meier. Cox proportional hazard model was used to
assess variables in multivariate analysis.
Results:
The mean age of all patients was 45.6 years. The median
follow-up period was 27 months. Basal group showed 20/24
patients (83.3%) with positive CK5/6, 21/24 patients (87.5%)
with positive EGFR and 17/24 patients (70.8%) with positive both
CK5/6 and EGFR. For recurrent event, 23/24 patients (95.8%) in
basal group versus 10/27 patients (37%) in non-basal group,
P=0.001. For death event, 19/24 patients (79.2%) in basal group
versus 5/27 patients (18.5%) in non-basal group, P=0.001. There
were significant worsened survival with basal group compared to
non-basal group (DFS and OS), P≤0.001. There was negative
significant impact of all prognostic factors on DFS in basal
group. Multivariate analysis revealed that rate of metastases
(95% C1 (1.603-3.370), OR= 2.307, P=0.001), high grade (95% C1
(1.631-8.52), OR= 3.729, P=0.002) and positive Ki 67> 14% (95%
C1 (0.029-0.634), OR=0.135, P=0.011) had retained their
independent prognostic value for DFS with basal-like tumors.
Conclusion:
TNBC basal-like is a poor prognostic factor for DFS and OS, need
more trials to support this prognostic power and allow the use
of effective specific therapeutic targets to improve future
image of this subtype.
[Ashraf F. Barakat, Fatma Z. Hussien, Dareen A. Mohamed and
Radwa M.
Orbey.
Clinical outcomes of Basal versus Non-Basal clone in Triple
Negative Breast Cancer patients.
Cancer Biology
2015;5(4):6-16]. (ISSN:
2150-1041).
http://www.cancerbio.net.
2. doi:10.7537/marscbj050415.02.
Keywords:
Triple negative breast cancer, immunohistochemistry, Basal
markers expression, CK5/6, EGFR, Survival. |
Full Text |
2
|
3
|
Assessment of costs and burden
associated with cancer chemotherapy in patients attending a
tertiary hospital in Zaria, Nigeria
Auwal A. Ahmad 1,
Titus Shekarau 1, Idris Abdullahi Nasir 2,
Zayyad Muhmmad Aminu 3, Shafi’u Muhammad 3,
Umar Mukhtar Danmusa 1
1
Department of Pharmaceutical
services, Ahmadu Bello University Teaching Hospital,
Shika-Kaduna State, Nigeria
2
Department of Medical Laboratory
Science, College of Medical Sciences, University of Maiduguri,
PMB 1069 Maiduguri, Borno state, Nigeria
3
Department of Clinical Pharmacy, Faculty of Pharmaceutical
sciences, Ahmadu Bello University, Zaria-Kaduna State, Nigeria
Correspondence address:
eedris888@yahoo.com
Abstract:
This study aimed to
determine the costs and burden associated with cancer
chemotherapy by calculating the direct costs with or without
co-morbidities in patients attending Ahmadu Bello University
Teaching Hospital (ABUTH) Zaria, Nigeria. This was retrospective
observational study conducted on cancer patients’ data as well
as cost details through the use of structured questionnaire
interview. These data were reviewed and analyzed for relevant
inferences. Healthcare associated cost were calculated based on
the total amount spent by the patients to that of total number
of patients. A total of 31 patients were enrolled, out of which
26 supplied complete health care-related cost details required
for the study. The average cost for cancer chemotherapy was
29034.4 (Nigerian Naira), they cost was least among those within
the age group 26-35 years, 20405 (Nigerian Naira) and highest
among 51-70 years, 62550 (Nigerian Naira). 19 (69.3%) of
patients complained of loss of productivity for over > 7 days/
month while 4, (13.4%) never had any decline in their
productivity. 13 (50%) of the patients strongly agreed with
difficulty in financing cancer chemotherapy while all strongly
supports the need for inclusion of chemotherapeutic agents in
the national health insurance scheme and the need for government
and non-government interventions through cost relieve programs.
The average cost of cancer chemotherapy at ABUTH Zaria was
29034.4 (Nigerian Naira). Considering the per capita income of
average Nigerian, cancer chemotherapy places high financial
burden in these patients. This thus justify the need for
governmental and non-governmental interventional programs
towards relieving these patients.
[Auwal
A. Ahmad, Titus Shekarau, Idris Abdullahi Nasir, Zayyad Muhmmad
Aminu, Shafi’u Muhammad, Umar Mukhtar Danmusa. Assessment of
costs and burden associated with cancer chemotherapy in patients
attending a tertiary hospital in Zaria, Nigeria.
Cancer Biology
2015;5(4):17-21].
(ISSN:
2150-1041).
http://www.cancerbio.net.
3. doi:10.7537/marscbj050415.03.
Key words:
Health care cost, cancer chemotherapy. Cost analysis |
Full Text |
3
|
4
|
Second Malignancy in a Patient
with Long Survival from Solitary Plasmacytoma Previously Treated
with Radiation
* A. A. Adenipekun **M.A Jimoh, *T.N Elumelu
*Department of Radiotherapy College of Medicine, University of
Ibadan
**Dept. of Radiotherapy, University College Hospital, Ibadan.
Email-
adenipek2000@yahoo.com
Abstract:
We report a case of a 39 year- old man with second malignancy 13
years after chemo-radiation therapy for solitary plasmacytoma of
the fontal bone. The risk of second cancers is a well- known
adverse late effect of radiation therapy. However, this risk may
be less with the use of proton- beam therapy, the patient
actually presented with nasal bleeding of 5 years duration and
progressive swelling of the face of 2 years duration with
associated nasal obstruction and weight loss. Examination
revealed a bilateral purulent conjunctival hyperemia. Direct
examination revealed swelling on the frontal sinus and swelling
over the antrum. CT brain showed malignant and vascular tumor of
the frontal bone involving the nasal bones and paranasal sinuses
and compressing the frontal brain tissues. This was
histologically confirmed. The frontal bone was completely
destroyed and frontal brain tissue was covered only by skin. He
received 6 courses of 3 weekly combination chemotherapy with
total of 60Gy of radiotherapy to the left and lateral face and
10Gy to the anterior face with complete regression. He was on
follow up for 3 years during which the lesion was controlled
with no evidence of recurrence nor neutral deficit. Patient was
however lost to follow up for 10 years. He presented again after
13 years of treatment with complaints of painful ulcer on the
right lower mandible and biopsy of lesion came as squamous cell
carcinoma. This was completely different from the firs histology
of plasmacytoma for which he received external beam
radiotherapy, however the site of present disease was in the
field of previous treatment. This is therefore suggestive of a
second malignancy appearing 13 years after the initial external
beam radiotherapy. He received cisplatin and 5fluorourasil in
preparation for further radiotherapy after chemotherapy patient
lost to follow up again and eventually was confirmed to have
died at home.
[A. A. Adenipekun, M.A Jimoh, T.N
Elumelu. Second Malinancy In A Patient With Long Survival
From Solitary Plasmacytoma Previously Treated With Radiation.
Cancer Biology
2015;5(4):22-25].
(ISSN:
2150-1041).
http://www.cancerbio.net. 4.
doi:10.7537/marscbj050415.04.
Keywords:
External beam, Radiotherapy, Chemotherapy, Radiation, Oral
cavity cancer, Second cancer. |
Full Text |
4
|
5
|
Cyclophosphamide with Adjuvant Chemotherapeutic Drugs Induces
Epigenetic Changes in Hepatocellular Carcinoma Cells
Hussein Sabit1*, Arwa
S. Abdel-Sattar1, Shimaa E. Abdel-Ghany2,
Asmaa M. Abushady3, Osama A. M. Said1
1 College of
Biotechnology, Misr University for Science and Technology, Giza,
Egypt,
2 Research and
Development Center, Misr University for Science and Technology,
Giza, Egypt,
3
Department of
Genetics, Fac. Agric., Ain Shams University, Cairo Egypt.
* Corresponding author: mailto:
hussein.sabit@must.edu.eg.
Abstract:
Cancer remains the major health threat worldwide; therefore, the
extensive search for potent cancer-controlling agents are still
a big demand. Hepatocellular carcinoma (HCC) is a type of cancer
widespread in the developing countries. In the present study,
the role of Cyclophosphamide and drug combinations (including
Erlotinib, Temozolomide, Vorinostat, and Sodium Phenylbutyrate)
as DNA methyltransferase (DNMT) and Histone deacetylase (HDAC)
inhibitors was evaluated. Two concentrations of each drug i.e.,
3µM and 5µM for one incubation period of 72 h were applied.
Trypan blue test was used to count the number of viable cells
before and after treatments. DNA degradation assay was employed
to evaluate the effect of Cyclophosphamide and a combination of
drugs on the integrity of genomic DNA. Global methylation was
also quantified via measuring the concentration of
5-Methylcytidin in the treated and un-treated HCC cells. Data
obtained indicated that treating HCC cells with Cyclophosphamide
either alone or in combination with other drugs has resulted in
a significant decrease in the number of viable cells. Meanwhile,
global DNA methylation data analysis showed that three
combinations have resulted in hypomethylating the whole genome
of HCC cells (Cyclophosphamide with Erlotinib, Cyclophosphamide
with Sodium Phenylbutyrate, and Cyclophosphamide with Vorinostat).
Although in vitro data need to be tested on the
pre-clinical level, the best combination, Cyclophosphamide
combined with Sodium Phenylbutyrate, might be recommended to be
used in treating HCC in vivo.
[Hussein Sabit, Arwa S. Abdel-Sattar, Shimaa E. Abdel-Ghany,
Asmaa M. Abushady and Osama A. M. Said. Cyclophosphamide with
Adjuvant Chemotherapeutic Drugs Induces Epigenetic Changes in
Hepatocellular Carcinoma Cells.
Cancer Biology
2015;5(4):26-34].
(ISSN:
2150-1041).
http://www.cancerbio.net.
5.
doi:10.7537/marscbj050415.05.
Keywords:
Hepatocellular carcinoma, HCC, Epigenetics, chemotherapeutic
drugs. |
Full Text |
5
|
6
|
Bladder
preservation by neoadjuvant chemotherapy followed by gemcitabine
as radiosensitizer for muscle-invasive transitional cell
carcinoma of the urinary bladder after maximal TURBT
Alaa fayed, M.D.1,
Abd el motaleb mohammed, M.D.1, Maged M. Ali, M.D.2,
Esam E.A. Dessoky, M.D.2
1Clinical
Oncology and Nuclear Medicine Department, Faculty of Medicine,
Zagazig University , Egypt.
2Urology
Department, Faculty of Medicine Zagazig University, Egypt.
fayed_alaa@yahoo.com
Abstract:
Objectives:
To evaluate prospective phase II study of neoadjuvant
chemotherapy and gemcitabine as radiosensetizer in conservative
management of muscle-invasive transitional cell carcinoma of the
urinary bladder. Patients and methods: Forty eight
patients with transitional cell carcinoma, stage T2b-T4aN0M0,
bladder cancer underwent maximal TURBT followed by neoadjuvant
chemotherapy carboplatin AUC5 D1 and gemcitabine 1000 mg/m2
D1and D8 repeated every 21 days for 2 cycles followed by
concurrent radiation 65Gy with Gemcitabine given intravenously
at 100 mg/m2 on days 1, 8, 15, 22, 29, 36. The end
points were tumor response, toxicity and survival. Results:
The neoadjuvant as well as concurrent chemoradiotherapy were
tolerated with low toxicity rates as the following, Urinary
Bladder irritative symptoms developed in 2 patients (4.1%) and
successfully managed with antimuscarinic. Neutropenia occurred
in 4 patients (8.3%) while febrile neutropenis in 1 patient
(2%). Nausea and vomiting occurred in 6 patients (12.5%) while
nephrotoxicity occurred in 2 patients (4.1%). Complete response
was noted in 28 patients (58.3%). Partial response was observed
in 15 patients (31.25%). At time of analysis, there were
fourteen deaths (29.1%) due to bladder cancer. Three-year cancer
specific survival (CSS) and overall survival (OS) were 69.9% and
66.6%. Twenty one patients (43.7%) were tumor free and kept
their bladder at time of analysis. Conclusion:
Neoadjuvant chemotherapy followed by gemcitabine as
radiosensitizer for muscle-invasive transitional cell carcinoma
of the urinary bladder was tolerable with good bladder
preservation and overall survival.
[Alaa fayed, Abd el motaleb mohammed, Maged M. Ali, and Esam E.A.
Dessoky. Bladder
preservation by neoadjuvant chemotherapy followed by gemcitabine
as radiosensitizer for muscle-invasive transitional cell
carcinoma of the urinary bladder after maximal TURBT. Cancer Biology 2015;5(4):35-41].
(ISSN:
2150-1041).
http://www.cancerbio.net.
6.
doi:10.7537/marscbj050415.06.
Keywords:
Bladder cancer, gemcitabine, radiosensetizer |
Full Text |
6
|
7
|
Prevalence Of Helicobacter pylori And Its Association
With Abo Blood Group In Asymptomatic, Ulcer Students Of Western
Delta University, Oghara, Nigeria
Mordi Raphael Mbadiwe 2
Braimah Mikalu Rashidat 1
Igere Bright 1
1
Western Delta University, Oghara, Delta State.
2
Benson Idahosa University, Benin city, Edo State
Corresponding author: Mordi Raphael Mbadiwe
Email:
Raphael_mordi@yahoo.com
Abstract:
This study aims to determine the involvement of Helicobacter.
pylori as a cause of abdominal discomfort and peptic ulcer,
and also to determine if there is any correlation with ABO blood
group in asymptomatic individuals. Blood samples were collected
from (fifty) healthy individuals, consisting of 8 males and 42
females aged between 17-30 years (mean 23.5 years). This was
accompanied with a questionnaire for demographic data. H.
pylori one step test kit was used. ABO blood group and
rhesus factors were determined by slide agglutination using
serum that was serially diluted. Results showed that 640/0
were sero-positive for H pylori. Of the seropositive
subjects, 62.50/0 (n=5/8) were male and
35.7% (n=15/42) were females. The frequency of the ABO and
rhesus positive (Rh+) blood groups among seropositive subject
was (A=6%, B=8%, AB=4% with rhesus positive 58% and rhesus
negative 6%) and among seronegative subjects it was (A=8%, B=0%,
AB=0%, 0=28% with rhesus positive 34% and rhesus negative 2%).
The results of this study, showed that ABO blood group and
rhesus compatibility greatly influenced the seropositivity for
H pylori infection. Further dilution of the blood samples
showed a clear significant rise in titer up to 1:160. The
prevalence of cases after the dilution dropped in the following
manner (1:20=26%, 1:40=12%, 1:80=8%, and 1:160=2%) the
seronegative cases increased during the dilution as (1: 20=74%,
1:40=92%, and 1:160=98%). Prevalence of H. pylori
infection still remains high after serial dilution. Conclusion:
The detection of high prevalence of H. pylori infection
among asymptomatic individuals and the involvement of ABO blood
groups necessitates blood screening for every individual
especially those that possess the blood groups that are at most
risk of infection.
[Mordi
Raphael Mbadiwe
, Braimah Mikalu Rashidat, Igere Bright.
Prevalence Of Helicobacter pylori And Its Association
With Abo Blood Group In Asymptomatic, Ulcer Students Of Western
Delta University, Oghara, Nigeria.
Cancer Biology
2015;5(4):42-67].
(ISSN:
2150-1041).
http://www.cancerbio.net.
7.
doi:10.7537/marscbj050415.07.
Key words:
Seroprevalence; Asymptomatic individuals; ABO blood group;
Helicobacter pylori; Infection. |
Full Text |
7
|
8
|
Prognostic Value of Doppler
Perfusion Index in Early Colorectal Cancer for Adjuvant
Chemotherapy
Ahmad Alhosainy 1,
Ahmed Z Alattar1, Abd Elmotaleb Mohamed1
Inas M.Elfiki2, Jihan A. Shawky3
and Abd Elhafez M.
Elsheweal4
1Clinical
Oncology & Nuclear Medicine, 2 Radiology,
3
Tropical Medicine, and
4 General Surgery Departments, Faculty of Medicine,
Zagazig University, Zagazig, Egypt
ahmedenbedo@hotmail.com
Abstract: Objective: Until now there is no clear recommendation
for the application of adjuvant chemotherapy in patients with
colorectal cancer stage Dukes A, despite undergoing
apparently curative resection, are at high risk of recurrence.
We assessed whether the doppler perfusion index (DPI; ratio of
hepatic arterial to total liver blood flow) could be used to
select patients who should receive adjuvant chemotherapy. Aim:
to assess the value of DPI for selecting patients with early
stage colorectal cancer undergoing curative surgery to receive
adjuvant chemotherapy. Patients and methods: fifty
patients (40 males and 10 females, median age 61, range 23-68)
undergoing apparently curative surgery for colorectal cancer
were staged using Dukes' classification. In addition, DPI was
measured before surgery by means of a duplex/color Doppler
sonography. A DPI value of at least 0.3 was defined as abnormal.
After surgery patients were followed up for recurrences every
three months for 3 years. Results: patients with normal
DPI had recurrence-free survival of 80% and overall survival of
85%, compared with 43.3% and 60% for those with abnormal DPI
values. Conclusion: we conclude that; DPI can be used to
identify patients with early stage colorectal cancer at high
risk of recurrence who are in need for adjuvant treatment
[Ahmad Alhosainy, Ahmed Z.
Alattar, Abd Elmotaleb Mohamed, Inas M. Elfiki, Jihan A. Shawky,
and Abd Elhafez M. Elsheweal.
Value of Doppler Perfusion Index
in Early Colorectal Cancer for Adjuvant Chemotherapy. Cancer Biology 2015;5(4):68-75].
(ISSN:
2150-1041).
http://www.cancerbio.net.
8. doi:10.7537/marscbj050415.08.
Key words:
DPI, colorectal cancer, Dukes’ stage A and B. |
Full Text |
8
|
9
|
Environmental Risk Posed by
Heavy Metal Concentration in the Tissue of Tympanotonus
fuscatus from Calabar River, Nigeria.
George, Ubong Uwem.
1Department
of Zoology and Environmental Biology University of Calabar,
Calabar, Cross River State, Nigeria.
*Corresponding author:
talk2georgeubong@gmail.com
Abstract:
Environmental
pollution associated with heavy metal concentrations is an
emerging issue in most developed and undeveloped countries.
Calabar River has been reported to be open to several inputs
from industrial activities within the environment. This research
was therefore carried out to determine the heavy metal
concentrations in tissues of Tympanotonus fuscatus
within the following months (August, September and October,
2014). From the results it was found out that the mean
concentration of heavy metal in month of August followed the
trend: Zn>Cu>Fe>Cd>Pb>Cr, while in
September: Fe>Cu>Zn>Pb>Cd>Cr and October trend was Fe>Cu>Zn>Pb>Cr>Cd.
The high concentration of Zn (0.091 mg/l) in month of August can
be attributed to dissolution of zinc from oil pipelines fixed
across the water body by oil companies that are accumulated in
tissues of T. fuscatus. Fe concentration was found to be
higher as compared to other metals in month of September (0.073
mg/l) and October (0.075 mg/l) and can be traced to the use of
iron coagulants or the corrosion of steel and cast iron pipes
during the process of water distribution.
[George, U. U. Environmental Risk Posed by Heavy Metal
Concentration in the Tissue of Tympanotonus fuscatus from
Calabar River, Nigeria.
Cancer Biology
2015;5(4):76-79].
(ISSN:
2150-1041).
http://www.cancerbio.net.
9.
doi:10.7537/marscbj050415.09.
Keywords:
Environmental Risk, Heavy Metal, Concentration, Tissue,
Tympanotonus fuscatus, Calabar River |
Full Text |
9
|
10
|
High or Low Ligation of the Inferior Mesenteric Artery during
Curative Surgery for Rectal Cancer
Ali Zedan1, Haisam Atta2,
Adel gabr3, and Tareq
Salah4
1Department
of Surgical Oncology, South Egypt Cancer Institute (SECI),
Assiut University, Egypt
2Department
of Radiology / Oncoradiology South Egypt Cancer Institute
(SECI), Assiut University, Egypt
3Department
of Medical Oncology, South Egypt Cancer Institute (SECI), Assiut
University, Egypt
4Department
of Clinical Oncology, Faculty of Medicine, Assiut University,
Egypt.
alizedan73@yahoo.com
Abstract:
Background: In rectal cancer surgery.
The position of arterial ligation
can affect genito-urinary function, bowel function, oncological
outcomes, and the incidence of anastomotic leakageInlow ligation
preservation of the autonomic nerve, increased blood supply,
decrease in anastomotic leakage. Oncological safety and
tension-free anastomosis remain drawbacks. High ligation
decrease perfusion and innervation of the proximal limb
allows for enbloc dissection of the node metastases at and
around the origin of the IMANo conclusive evidence to.
Improved survival
Objective compare complication and Oncological outcomes between
high and low tie of IMA Methods a retrospective analysis of 114
patients
who were operated on for rectal cancer during the period of 5
years [1 January 2007 – 31 December 2011] at the south Egypt
cancer Institute of Assuit University..In 38 patients (33.3%), a
high ligation76 patients (66.7%) were treated low IMA ligation).
in which the fatty tissue and metastatic nodes at the root of
the inferior mesenteric are removed (Dumpy) The pathologic grade
and stage of tumors was quite similar in both groups. Results
Nine patients (24%) in the high tie (HT) group and twenty
patients (26%) in the LT(low tie group)group received a
defunctioning stoma. The mean number of lymph nodes harvested in
the high tie group was 21 in the LT group, 18 (p = 0.35).
The mean number of positive lymph nodes in the high tie group
was 4 in the LT group, 3 (1–5); (p = 0.32). Two patients
had positive lymph nodes at the root of IMA, one in the High tie
group (2.7%) and one in the LT group (1.3)
Urinary dysfunction (7.9%) in Low tie group and (10.5%) in high
group p value (0.73). Sexual Dysfunction (10.5%) in LT
group (13.2%) in a high group (0.76), Gastrointestinal
Dysfunction (3.9%) in LT group, (5.3%) in a high group p
value (1.0) Anastomotic leakage (5.3%) in LT group (7.9%) in a
high group p value (0.68). Five years overall survival in
low IMA = 78.2±2.7% versus 79.7±3.3%, p value = 0.98 (NS)
Five years recurrence free survival in low IMA = 86.2±4.0%
versus 86.3±6.1%, p value = 0.82 (NS) Recurrence (11.8%) in LT
group, and (10.5%) in high group. Mortality occur in (2.6%) in
LT group, and (2.6%) in high group. Conclusion.
High ligation of the IMA does not significantly improve the
survival, when high ligation is not necessary, we prefer low
ligation. With the fatty tissue and metastatic nodes at the root
of the IMA are removed.
[Ali Zedan, Haisam Atta,Adel gabr, and Tareq Salah. High or Low
Ligation of the Inferior Mesenteric Artery during Curative
Surgery for Rectal Cancer.
Cancer Biology
2015;5(4):80-86].
(ISSN:
2150-1041).
http://www.cancerbio.net.
10. doi:10.7537/marscbj050415.10.
Keywords:Rectal
Cancer, Inferior Mesenteric Artery |
Full Text |
10
|
11
|
Prognostic Impact of Lymph
Nodes Metastases in
Hepatocellular Carcinoma
Alaa Maria and
Walid Al-Morsy.
Clinical Oncology
Department, Faculty of Medicine, Tanta University, Egypt
alaamaria1@hotmail.com
Abstract: Purpose:
Explore
the clinicopathological characteristics of HCC patients and
evaluate
the impact of lymph node (LN) metastasis on survival.
Material and Methods: Clinical
data of 261 HCC patients treated at Clinical Oncology
Department, Tanta University were
retrieved from the collected database. Patients with LNs
metastases
were compared with those without LNs
metastases. Results:
Patients without LNs metastases had a significantly better
Child-Pugh score (p=0.004), smaller size of intra-hepatic
focal lesion (p=0.003), and better
tumor morphology (p=0.003).
The most frequent extra-hepatic metastases sites were LNs
(44.4%) and bone (43.3%). The commonest LN sites were the para-aortic
(25.7%),
porta-hepatis (21.8%).
Patients received active treatment to control intra-hepatic
disease had significantly higher median survival than patients
underwent only supportive and palliative measures (p<0.001).
The 1- and 2-year overall survival (OS) rates were 28.7% and
5.3% respectively. Six factors (performance status, size of
primary intra-hepatic tumor, ascites, Child-Pugh score, portal
vein thrombosis, and LNs metastases) significantly affect the OS
rate in univariate analysis (p<0.001, =0.001, <0.001,
<0.001, =0.048 and <0.001, respectively). On multivariate
analysis, performance status, ascites and LN
metastases were independent
risk factor of OS (p<0.001, =0.017, and =0.008
respectively). Conclusion: Lymph node
metastasis was the commonest
site of extra-hepatic spread of HCC and
presented with a multifocal, large tumor size (≥
5 cm) with poor Child-Pugh score and
was one of the independent risk factors affecting OS. Selected
patients with extra-hepatic spread may gain benefit from
treatment of intra-hepatic lesions.
[Alaa Maria and
Walid Al-Morsy.
Prognostic Impact of Lymph
Nodes Metastases in Hepatocellular Carcinoma.
Cancer Biology 2015;5(4):87-93].
(ISSN: 2150-1041).
http://www.cancerbio.net.
11. doi:10.7537/marscbj050415.11.
Key words:
Hepatocellular carcinoma, lymph nodes
metastases, prognostic factors. |
Full Text |
11
|
12
|
Molecular and
Cytogenetic Markers in Acute Myeloid Leukemia
Mohammed Albalawi1, Mohammed
Al Shahrani2 and Ghaleb Elyamany3
1Department
of Medicine, College of Medicine, Taibah University, Madinah,
Saudi Arabia
2Dept.
of Pediatric Hematology/Oncology, Prince Sultan Military Medical
City, Riyadh, Saudi Arabia
3Dept.
of Central Military Laboratory and Blood Bank, Prince Sultan
Military Medical City,
Riyadh, Saudi Arabia and Department of Hematology, Theodor
Bilharz Research Institute, Egypt.
albalawi_21@hotmail.com
Abstract:
Acute myeloid leukemia (AML) is a disease of hematopoietic
progenitor cells with acquisition of heterogeneous genetic
abnormalities that cause abnormal cell growth, proliferation and
differentiation. Cytogenetic
abnormality is considered an important prognostic factor in AML
patients. AML patients are prognostically classified into three
groups (favorable, intermediate, and poor) based on their
molecular and cytogenetic analysis. Clonal chromosomes
alterations are detected in approximately 50-55% of adults with
AML. However, 40% to 49% of adults and 25% of children with AML,
have no detectable chromosomal abnormality can be found on
standard cytogenetic analysis. These cytogenetically normal (CN)
patients have been classified as an intermediate-risk. Recently,
with the advent of next generation sequencing, different
molecular genetic abnormalities have been found in AML such as
DNMT3A, TET2, IDH1/2, NRAS, KRAS,
BCOR, RUNX1, and WT1. However, the
significance of many of these gene mutations is unclear.
[Mohammed Albalawi,
Mohammed Al Shahrani and
Ghaleb Elyamany.
Molecular and Cytogenetic Markers in Acute Myeloid Leukemia.
Cancer Biology
2015;5(4):94-106].
(ISSN:
2150-1041).
http://www.cancerbio.net.
12. doi:10.7537/marscbj050415.12.
Keywords:
Acute myeloid leukemia (AML); Molecular Genetic Markers; NPM1;
FLT3-ITD; CEBPA |
Full Text |
12
|
13
|
Concurrent Chemoradiotherapy with Weekly
Docetaxel and Cisplatin for Locally Advanced Head and Neck
Cancer
Ola Nabih1, Hoda H. Essa1,
Reham Abdel-Wahab1,4, Nagham Nabil2, Dalia
G.Yasien3
1Department
of Clinical Oncology, Faculty of Medicine, Assiut University,
Assiut, Egypt
2Radio-Diagnosis,
Faculty of Medicine, Assiut University, Assiut, Egypt
3Otolaryngology,
Faculty of Medicine, Assiut University, Assiut, Egypt
4Department
of Gastrointestinal Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, Texas, USA
olanabih1980@gmail.com
Abstract: Background:
Concurrent
chemoradiotherapy (CCRth) using cisplatin-based regimens are the
standard of care in head and neck squamous cell carcinoma (HNSCC).
However, the addition of docetaxel to the treatment regimen
showed survival improvement. Objectives: Our study aims
to evaluate the efficacy and toxicity of CCRth with weekly
docetaxel and cisplatin in patients with locally advanced HNSCC.
Patients and Methods: Between March 2010 and April 2012,
we enrolled thirty stage III and IVA HNSCC patients.
We treated them with 70Gy conventionally fractionated
radiotherapy (Rth) concurrently with weekly cisplatin and
docetaxel, both given as one hour infusion of 20mg\m2
that administered 30 min before Rth.
Results:
The median follow-up period was 23months (range,
2 –53 months).The mean age of the patients was 59 years (range,
29–72 years). The most common primary tumor site was the larynx
(53.3%), followed by the hypopharynx (26.7%).
64.5% of patients had N2/N3 disease and
76.7% had T3/T4 disease. Among
30 patients, 13 (43.3%) achieved complete response (CR),
11(36.7%) achieved a partial response (PR), 2(6.7%) had stable
disease (SD) and 4 patients (13.3%) had progressive disease
(PD). The 2-year overall survival (OS) and progression-free
survival (PFS) was 83.3% and 66.7%, respectively with well
tolerable toxicities. Conclusions: Our study concluded
that concurrent administration of weekly cisplatin and docetaxel
is a well tolerable promising regimen that can induce only
minimal myelosuppression.
[Ola Nabih, Hoda H. Essa, Reham Abdel-Wahab,
Nagham Nabil, Dalia G. Yasien.
Concurrent Chemoradio therapy with Weekly Docetaxel and
Cisplatin for Locally Advanced Head and Neck Cancer.
Cancer Biology
2015;5(4):107-112].
(ISSN:
2150-1041).
http://www.cancerbio.net.
13.
doi:10.7537/marscbj050415.13.
Keywords:
Locally advanced head and neck cancer, chemoradiotherapy,
cisplatin, docetaxel. |
Full Text |
13
|
14
|
The impact of
concurrent chemo-irradiation followed by surgery for locally
advanced cervical carcinoma
Ahmad M.
Alhosainy1, Nabila Hefzi1, Hussein M.
Abdeldayem2, Esam M. Hemat3
1Clinical
Oncology & Nuclear Medicine, 2Gynecology &
Obstetrics, and 3Radiology Departments, Faculty of
Medicine, Zagazyg University, Egypt.
ahosainy40@yahoo.com
Abstract:
Background:
In 1999, five
randomized clinical trails of concurrent platinum-based
chemoirradiation showed an overall survival benefits in patients
with stage IB2 to IVA disease. Consequently in the same year; a
subsequent trial performed by the National Cancer Institute of
Canada demonstrated no survival advantage for concurrent
platinum-based chemoradiation in stage IB to IVA cervical cancer
patients. The aim of this study was to evaluate the
results and morbidities of concurrent chemoirradiation followed
by surgery in those locally advanced disease patients.
Patients and methods: patients fulfilling the inclusion
criteria were planned to receive concurrent chemoirradiation in
the form of whole pelvis and para aortic lymph nodes (PALNs)
external beam irradiation with delivery of 45 Gy concurrently
with platinum, 40 mg /m2 per week, followed by
completion surgery 6-8 weeks post the end of chemoirradiation.
Results: fifty patients with a median age of 48 years
(range, 41-67 years), were assessed at the time of surgery; 35
patients (70%) had histologic residual disease (RD) in the
cervix. The sizes of the cervical RD were < 1 cm in 18 patients
(51.4%) while 48.6% (17 patients) had a residual disease ≥ 1 cm.
Postoperative complications were noted in 23 patients (46%). The
factors increasing the risk of post-operative complications were
radical hysterectomy compared with an extrafascial hysterectomy,
odds ratio (OR)1, (OR)2-1 (1.7-4); P=0.04 and the presence of
cervical RD>1 cm (OR2) (1.2-6.9), compared with no RD (P=0.011).
Conclusion: In this study, the size of the residual
disease (RD) and histologic nodal involvement were the
strongest, statistically significant risk factors. These results
confirm that the survival of patients treated with concurrent
chemoirrdiation followed by surgery in locally advanced cervical
carcinoma could potentially be enhanced by improving the rate of
complete response in the irradiated area (cervix, pelvis, and
PALNs) and by initially detecting patients with para-aortic
spread. So that treatment could be adapted in such patients, as
the completion of surgery increases the morbidities.
[Ahmad M.
Alhosainy, Nabila Hefzi, Hussein M. Abdeldayem, Esam M. Hemat.
The impact of concurrent chemo-irradiation followed by
surgery for locally advanced cervical carcinoma.
Cancer Biology
2015;5(4):113-123].
(ISSN:
2150-1041).
http://www.cancerbio.net.
14. doi:10.7537/marscbj050415.14.
Keywords:
locally advanced cervical carcinoma, concurrent chemoirradiation,
surgery |
Full Text |
14
|
15 |
Feasibility of qualitative low dose multidetector row computed
tomography in the diagnosis of breast cancer
Mahmoud H. El shoieby1, G. Seifeldein2, M.
Abd Ellah3, Tark. M. Elsabaa4 and Momin M.
Aly5
Departments Surgical Oncology1, Radiology3,
Pathology4 and Radiotherapy and Nuclear Medicine
5 South Egypt Cancer Institute, Egypt.
2Department
Radiology, Faculty of Medicine, Assiut University, Egypt.
E-mail:
elshoieby@live.co.uk
Abstract: Objective:
To evaluate the role of low dose multidetector row computed
tomography (MDCT) in detection and diagnosis of breast lumps and
axillary lymph node (ALNS). Patients and methods: Twenty
patients with 15 breast lumps pathologically proven malignant
underwent low-dose MDCT in supine position. Morphological
analysis of MDCT images (multiplanar reformation, maximal
intensity projection and 3-dimensional reconstruction) to assess
shape, size and attenuation and quantitative analysis was done
by measurement of time-density curves of both breast lumps and
abnormal ALNS. The results are confirmed by postoperative
histopathological reports. Results: 10 (50%) showed a
washout pattern, 6 (30%) showed a plateau pattern, and 4 (20%)
showed a persistent pattern. Fifteen out of 20 patients
underwent surgery, where 3 patients underwent modified radical
mastectomy and 12 patients performed breast conservative
surgery, and the pathologic findings revealed 10 invasive ductal
carcinoma, 4 invasive lobular carcinoma and 1 metaplastic.
Significant mean difference was found between the MDCT
measurement of the mass and measurement of pathological specimen
as well as ALNS measurement (p <0.001). Regarding detection of
positive ALNS, MDCT has accuracy 80.4%, sensitivity 80.4% and
specificity 80%, positive predictive value 76.7% and negative
predictive value 83.3%. Conclusion: MDCT may represent a
useful investigative tool for the diagnosis of breast cancer and
accompanying ALNS.
[Mahmoud H.El shoieby, G.
Seifeldein, M. Abd Ellah, Tark. M. Elsabaa and Momin M. Aly.
Feasibility of qualitative low dose multidetector row computed
tomography in the diagnosis of breast cancer. Cancer Biology 2015;5(4):124-129].
(ISSN:
2150-1041).
http://www.cancerbio.net.
15. doi:10.7537/marscbj050415.15.
Key words:
MDCT, time-density curve, Hounsfield unit, ALNS, breast cancer |
Full Text |
15 |
The manuscripts in this
issue were presented as online first for peer-review starting
from
October 16, 2015.
All comments are
welcome:
editor@sciencepub.net
For
back issues of the Researcher,
click here.
Emails:
editor@sciencepub.net
|